Related Experiment Video
Updated: May 9, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Transition of care from childhood/adolescence to adulthood in familial hypercholesterolemia
Ariana Maia1, Liliana Fonseca1, Isabel Palma1
1Serviço de Endocrinologia, Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal.
Insights
Familial hypercholesterolemia (FH) management requires early detection and genetic screening. This genetic disorder necessitates lifelong lipid-lowering therapy to prevent premature cardiovascular disease and improve patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Familial hypercholesterolemia (FH) is a prevalent genetic disorder causing high LDL-C levels.
- Elevated LDL-C from childhood significantly increases premature atherosclerotic cardiovascular disease risk.
Purpose of the Study:
- To outline strategies for improving early detection and genetic screening of FH.
- To provide recommendations for holistic, long-term management of FH patients.
- To emphasize seamless transition from pediatric to adult care for sustained adherence.
Main Methods:
- Review of current literature and clinical guidelines on FH management.
- Development of recommendations for screening programs and genetic testing.
- Framework for integrated care pathways, including transition services.
Main Results:
- Early identification and intervention are critical for mitigating cardiovascular risk in FH.
- Genetic testing aids in accurate diagnosis and family screening.
- Comprehensive management strategies improve quality of life and reduce mortality.
Conclusions:
- Effective screening, genetic testing, and timely lipid-lowering therapy are essential for FH patients.
- Continuity of care, especially during healthcare transitions, is vital for long-term treatment adherence and outcomes.
Abstract:
Familial hypercholesterolemia (FH) is a common genetic disorder with a co-dominant inheritance pattern, characterized by persistently elevated levels of atherogenic low-density lipoprotein cholesterol (LDL-C) and a significantly increased risk of premature atherosclerotic cardiovascular disease. Given that the cardiovascular risk associated with elevated LDL-C begins in early childhood and progresses over time, early identification and long-term management are crucial. Implementing effective screening programs, genetic testing, and timely initiation of lipid-lowering therapy are essential strategies to mitigate future coronary events, improve quality of life, and reduce morbidity and mortality. This document outlines strategies and recommendations to improve early detection, genetic screening, and holistic management of individuals affected by FH, with particular emphasis on facilitating a structured transition from pediatric to adult healthcare services to ensure continuity of care and sustained treatment adherence.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Cystic Fibrosis: Management
Sinus disease and chronic...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipids: Dietary Sources and Requirements

